Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
May 15 2020 - 6:16AM
Edgar (US Regulatory)
Filed Pursuant to Rule 433 under the Securities Act of 1933
Registration Statement No. 333-223095
Issuer Free Writing Prospectus, dated May 14, 2020
Boston Scientific Corporation
$1,700,000,000
Senior Notes Offering
Terms and Conditions — 5- and 10-Year Fixed Rate Notes
|
|
|
5-Year
|
|
10-Year
|
|
|
|
|
|
|
|
Issuer
|
|
Boston Scientific Corporation
|
|
Boston Scientific Corporation
|
|
|
|
|
|
|
|
Note Type
|
|
Senior Notes
|
|
Senior Notes
|
|
|
|
|
|
|
|
Form of Offering
|
|
SEC Registered
|
|
SEC Registered
|
|
|
|
|
|
|
|
Ratings(1)
|
|
Baa2/BBB-/BBB (Stable/Stable/Stable)
|
|
Baa2/BBB-/BBB (Stable/Stable/Stable)
|
|
|
|
|
|
|
|
Principal Amount
|
|
$500,000,000
|
|
$1,200,000,000
|
|
|
|
|
|
|
|
Trade Date
|
|
May 14, 2020
|
|
May 14, 2020
|
|
|
|
|
|
|
|
Settlement Date (T+2)
|
|
May 18, 2020
|
|
May 18, 2020
|
|
|
|
|
|
|
|
Maturity Date
|
|
June 1, 2025
|
|
June 1, 2030
|
|
|
|
|
|
|
|
Coupon
|
|
1.900% per annum
|
|
2.650% per annum
|
|
|
|
|
|
|
|
Yield to Maturity
|
|
1.910% per annum
|
|
2.667% per annum
|
|
|
|
|
|
|
|
Price to Public
|
|
99.952%
|
|
99.851%
|
|
|
|
|
|
|
|
Spread to Benchmark Treasury
|
|
Plus 160 basis points
|
|
Plus 205 basis points
|
|
|
|
|
|
|
|
Benchmark Treasury
|
|
0.375% UST due April 30, 2025
|
|
1.500% UST due February 15, 2030
|
|
|
|
|
|
|
|
Benchmark Treasury Yield
|
|
0.310%
|
|
0.617%
|
|
|
|
|
|
|
|
Benchmark Treasury Price
|
|
100-10 ¼
|
|
108-11
|
|
|
|
|
|
|
|
Interest Payment Dates
|
|
Semi-annually on June 1 and December 1
|
|
Semi-annually on June 1 and December 1
|
|
|
|
|
|
|
|
First Interest Payment Date
|
|
December 1, 2020
|
|
December 1, 2020
|
|
|
|
|
|
|
|
Make-whole Call
|
|
Prior to May 1, 2025, make-whole call at T+25 basis points
|
|
Prior to March 1, 2030, make-whole call at T+35 basis points
|
|
|
|
|
|
|
|
Par Call
|
|
On or after May 1, 2025
|
|
On or after March 1, 2030
|
|
|
|
|
|
|
|
Change of Control Repurchase Event
|
|
Putable at 101% of aggregate principal amount plus accrued and unpaid interest, if any, to, but not including, the date of repurchase
|
|
Putable at 101% of aggregate principal amount plus accrued and unpaid interest, if any, to, but not including, the date of repurchase
|
|
|
|
|
|
|
|
Day Count Basis
|
|
30/360
|
|
30/360
|
|
|
|
5-Year
|
|
10-Year
|
|
|
|
|
|
|
|
Minimum Denominations
|
|
$2,000 and integral multiples of $1,000 in excess of such amount
|
|
$2,000 and integral multiples of $1,000 in excess of such amount
|
|
|
|
|
|
|
|
CUSIP / ISIN
|
|
101137 AZ0 / US101137AZ01
|
|
101137 BA4 / US101137BA41
|
|
|
|
|
|
|
|
Joint Bookrunners
|
|
Barclays Capital Inc.
Citigroup Global Markets Inc.
J.P. Morgan Securities LLC
Wells Fargo Securities, LLC
BofA Securities Inc.
DNB Markets, Inc.
RBC Capital Markets, LLC
Scotia Capital (USA) Inc.
SG Americas Securities, LLC
|
|
Barclays Capital Inc.
Citigroup Global Markets Inc.
J.P. Morgan Securities LLC
Wells Fargo Securities, LLC
BofA Securities Inc.
DNB Markets, Inc.
RBC Capital Markets, LLC
Scotia Capital (USA) Inc.
SG Americas Securities, LLC
|
|
|
|
|
|
|
|
Co-Managers
|
|
Allied Irish Banks p.l.c.
BNP Paribas Securities Corp.
Goldman Sachs & Co. LLC
MUFG Securities Americas Inc.
Standard Chartered Bank
TD Securities (USA) LLC
U.S. Bancorp Investments, Inc.
|
|
Allied Irish Banks p.l.c.
BNP Paribas Securities Corp.
Goldman Sachs & Co. LLC
MUFG Securities Americas Inc.
Standard Chartered Bank
TD Securities (USA) LLC
U.S. Bancorp Investments, Inc.
|
Note:
(1) A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
The Issuer has filed a registration statement (including a preliminary prospectus supplement and accompanying prospectus) with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus supplement and accompanying prospectus if you request it by calling Barclays Capital Inc. toll-free at (888) 603-5847, Citigroup Global Markets Inc. toll-free at (800) 831-9146, J.P. Morgan Securities LLC collect at (212) 834-4533 or Wells Fargo Securities, LLC toll-free at (800) 645-3751.
Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Sep 2023 to Sep 2024
